Abstract
Five girls and one boy with precocious puberty have been treated for 2-4 yrs with D-TRP-6-LH-RH (0.45-1.5 mcg/kg/day s.c.). LH and FSH secretion assessed by LRH tests remained suppressed in 4 patients; in 2 “escape” FSH responsiveness was observed after 1½ and 3 3/4 yrs of therapy. In all girls E2 levels remained in the prepubertal range (< 20 pg/ml) with occasional transient increases up to 53 pg/ml. In the boy testosterone levels dropped from 245 to 45 ng/dl on starting therapy and starting 1½ yrs later showed some increase (mean testosterone during 3rd year of therapy: 88.11±36 ng/dl). Clinically all showed sustained arrest of gonadarche with adrenarche unaffected; 2 girls required additive antiandrogen therapy. In all growth slowed to prepubertal rate and the BA/CA was decreased, indicating an improved final height prognosis. There were no undesirable side effects and all patients showed good compliance. It is concluded that at present therapy with superactive LH-RH analogue is the treatment of choice for precocious puberty.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kauli, R., Kalter-Leibovici, O., Schally, A. et al. 190 LONG TERM THERAPY OF PRECOCIOUS PUBERTY WITH THE SUPERACTIVE LH-RH ANALOGUE D-TRP-6-LH-RH. Pediatr Res 19, 635 (1985). https://doi.org/10.1203/00006450-198506000-00210
Issue Date:
DOI: https://doi.org/10.1203/00006450-198506000-00210
This article is cited by
-
Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins
European Journal of Pediatrics (1988)